02 February 2020: Sysmex and RIKEN Innovation Sign a Comprehensive Collaborative Agreement

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and RIKEN Innovation Co., Ltd. (HQ: Saitama, Japan; President and CEO: Yoshihiro Aburatani) have signed a partnership agreement to use the research results from National Research and Development Institute RIKEN (HQ: Saitama, Japan; President: Hiroshi Matsumoto) to jointly create new businesses and return benefits to society.

30 January 2020: Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.

23 January 2020: Sysmex Receives Regulatory Approval in China of an in Vitro Diagnostic Reagent to Help Diagnose Breast Cancer Lymph Node Metastasis Using the OSNA™ Method

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received regulatory approval on December 9, 2019 from China’s National Medical Products Administration (NMPA) for LYNOAMP™ BC, an in vitro diagnostic reagent. Our system to test for breast cancer lymph node metastasis using the OSNA™ method has received Class III1 regulatory approval as the first product for lymph node metastasis testing using a molecular biological technique.

06 January 2020: Sysmex Launches Gene Testing Kit for Blood Cancer (ipsogen JAK2 DX Reagent)

First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms.
Sysmex Corporation (HQ: Kobe, Japan; Chairman & CEO: Hisashi Ietsugu) announces its launch of the ipsogen JAK2 DX reagent. The company received marketing approval on the reagent on December 19, 2018. This product is a gene testing kit that measures the JAK2V617F mutation1 quantitatively, used in the diagnosis of certain hematopoietic tumors generally referred to as blood cancers, specifically polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).